MCID: SQM006
MIFTS: 69

Squamous Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 50 29 14 69
Epidermoid Carcinoma 12 50
Squamous Cell Cancer 12 52
Squamous Cell Carcinoma of the Skin 29
Squamous Cell Carcinoma - Category 69
Malignant Squamous Cell Neoplasm 69
Squamous Cell Carcinoma of Skin 69
Malignant Squamous Cell Tumor 12
Squamous Cell Carcinoma Nos 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 50
Carcinoma, Squamous Cell 50
Neoplasms, Squamous Cell 42
Carcinoma Squamous Cell 52
Squamous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1749
NCIt 47 C2929

Summaries for Squamous Cell Carcinoma

NIH Rare Diseases : 50 squamous cell carcinoma (scc) is the second most common skin cancer. scc most often affects individuals who are exposed to large amounts of sunlight. it is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. the most common causes of scc are radiation from the sun and arsenic exposure. with appropriate treatment, it is usually curable. last updated: 6/22/2011

MalaCards based summary : Squamous Cell Carcinoma, also known as epidermoid carcinoma, is related to bladder squamous cell carcinoma and middle ear squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma is DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Erbitux and Intron A have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and lymph node, and related phenotypes are Decreased viability and cellular

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

Wikipedia : 72 Squamous cell carcinomas, also known as epidermoid carcinoma are a number of different types of cancer... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 762)
id Related Disease Score Top Affiliating Genes
1 bladder squamous cell carcinoma 34.7 CCND1 CDKN2A TP53
2 middle ear squamous cell carcinoma 34.7 CDKN2A EGFR TP53
3 esophagus squamous cell carcinoma 34.5 CDKN2A PTEN PTGS2 SERPINB3 TP53
4 trachea squamous cell carcinoma 34.0 CCND1 CDKN2A EGFR ERBB2 HRAS PTEN
5 bladder urachal squamous cell carcinoma 33.7 CDKN2A EGFR TP53
6 nasopharyngeal carcinoma 33.3 CDKN2A EGFR PTEN TP53
7 prostate cancer 32.2 CCND1 EGFR ERBB2 GSTP1 HRAS PTEN
8 adenocarcinoma in situ 31.3 CDKN2A HRAS TP53
9 lymphopenia 31.3 EGFR PTEN TP53
10 lung cancer 31.2 CCND1 CDKN2A DDR2 DLEC1 EGFR ERBB2
11 mantle cell lymphoma 31.1 CDKN2A EGFR PTEN TP53
12 atrophic gastritis 30.9 CDKN2A PTGS2 TP53
13 molluscum contagiosum 30.7 CDKN2A EGFR SERPINB3 TP53 WWOX
14 ductal carcinoma in situ 30.7 CCND1 CDKN2A EGFR ERBB2 TP53
15 peritoneal mesothelioma 30.6 CCND1 HRAS PTEN TP53
16 apocrine adenoma 30.6 CCND1 CDKN2A GSTP1 TP53
17 ovarian brenner tumor 30.5 CDKN2A EGFR GSTP1 PTEN TP53
18 hepatocellular carcinoma 30.5 CCND1 CDKN2A CTTN GSTP1 PTEN PTGS2
19 endocervicitis 30.3 ERBB2 TP53
20 colorectal cancer 29.8 CCND1 CDKN2A EGFR ERBB2 GSTP1 HRAS
21 squamous cell carcinoma, head and neck 12.4
22 lung squamous cell carcinoma 12.3
23 tongue squamous cell carcinoma 12.3
24 basaloid squamous cell carcinoma 12.3
25 conjunctival squamous cell carcinoma 12.3
26 adenoid squamous cell carcinoma 12.3
27 oral squamous cell carcinoma 12.3
28 keratinizing squamous cell carcinoma 12.3
29 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal 12.3
30 cervical squamous cell carcinoma 12.2
31 gastric squamous cell carcinoma 12.1
32 skin squamous cell carcinoma 12.1
33 nasal cavity squamous cell carcinoma 12.1
34 vulva squamous cell carcinoma 12.1
35 colon squamous cell carcinoma 12.1
36 endometrial squamous cell carcinoma 12.1
37 anal canal squamous cell carcinoma 12.1
38 anal squamous cell carcinoma 12.1
39 renal pelvis squamous cell carcinoma 12.1
40 squamous cell carcinoma of the pancreas 12.1
41 gallbladder squamous cell carcinoma 12.1
42 anal margin squamous cell carcinoma 12.1
43 maxillary sinus squamous cell carcinoma 12.1
44 ovarian squamous cell carcinoma 12.0
45 bone squamous cell carcinoma 12.0
46 squamous cell carcinoma of the oral tongue 12.0
47 esophageal basaloid squamous cell carcinoma 12.0
48 tonsil squamous cell carcinoma 12.0
49 frontal sinus squamous cell carcinoma 12.0
50 microinvasive cervical squamous cell carcinoma 12.0

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.55 EGFR HRAS
2 Decreased viability GR00107-A-1 10.55 TGFBR2
3 Decreased viability GR00221-A-1 10.55 TGFBR2 CDKN2A DDR2 DLEC1 EGFR HRAS
4 Decreased viability GR00221-A-2 10.55 DDR2 DLEC1 HRAS
5 Decreased viability GR00221-A-3 10.55 ERBB2 TGFBR2 CDKN2A HRAS
6 Decreased viability GR00221-A-4 10.55 ERBB2 TGFBR2 CDKN2A DDR2 EGFR
7 Decreased viability in esophageal squamous lineage GR00235-A 10 CCND1 CDKN2A DDR2 ERBB2 HRAS ING1
8 Increased cell death HMECs cells GR00103-A-0 9.63 EGFR GSTP1 PTEN TGFBR2 TP53 WWOX
9 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CDKN2A PTEN RB1 TP53 WWOX
10 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CCND1 CDKN2A PTEN RB1 TP53 TP63
11 Increased cell viability after pRB stimulation GR00230-A-1 9.26 DDR2 EGFR ERBB2 TGFBR2

MGI Mouse Phenotypes related to Squamous Cell Carcinoma:

44 (show all 26)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 ING1 PTEN PTGS2 RB1 TGFBR2 TP53
2 growth/size/body region MP:0005378 10.45 RB1 TGFBR2 TP53 TP63 WWOX CCND1
3 cardiovascular system MP:0005385 10.43 CCND1 CDKN2A CTTN DDR2 EGFR ERBB2
4 endocrine/exocrine gland MP:0005379 10.43 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
5 behavior/neurological MP:0005386 10.4 TP53 TP63 CCND1 CDKN2A DLEC1 ERBB2
6 homeostasis/metabolism MP:0005376 10.4 ING1 PTEN PTGS2 RB1 TGFBR2 TP53
7 mortality/aging MP:0010768 10.37 CCND1 CDKN2A CTTN DDR2 EGFR ERBB2
8 immune system MP:0005387 10.36 CDKN2A CTTN EGFR ING1 PTEN PTGS2
9 hematopoietic system MP:0005397 10.31 CCND1 CDKN2A CTTN EGFR ING1 PTEN
10 digestive/alimentary MP:0005381 10.3 TP63 CCND1 CDKN2A EGFR ERBB2 PTEN
11 neoplasm MP:0002006 10.3 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
12 embryo MP:0005380 10.29 CDKN2A CTTN EGFR ERBB2 PTEN PTGS2
13 integument MP:0010771 10.28 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
14 craniofacial MP:0005382 10.26 TP53 TP63 CCND1 DDR2 EGFR ERBB2
15 nervous system MP:0003631 10.21 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
16 muscle MP:0005369 10.18 CDKN2A DDR2 EGFR ERBB2 PTEN PTGS2
17 adipose tissue MP:0005375 10.17 DDR2 EGFR PTEN PTGS2 RB1 TGFBR2
18 no phenotypic analysis MP:0003012 10.14 PTGS2 RB1 SART1 TP53 TP63 WWOX
19 liver/biliary system MP:0005370 10.11 CDKN2A EGFR PTEN PTGS2 RB1 TGFBR2
20 limbs/digits/tail MP:0005371 10.07 DDR2 EGFR ERBB2 PTEN RB1 TP53
21 normal MP:0002873 10.07 CCND1 EGFR ERBB2 HRAS PTEN PTGS2
22 reproductive system MP:0005389 10.07 PTEN PTGS2 RB1 TP53 TP63 WWOX
23 respiratory system MP:0005388 9.97 HRAS PTEN PTGS2 RB1 SERPINB4 TGFBR2
24 skeleton MP:0005390 9.77 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
25 pigmentation MP:0001186 9.72 CDKN2A EGFR PTEN RB1 TP53
26 vision/eye MP:0005391 9.32 CCND1 CDKN2A DDR2 EGFR PTEN PTGS2

Drugs & Therapeutics for Squamous Cell Carcinoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erbitux 17 46 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 567)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3 99011-02-6 57469
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
5
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
6
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
8
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
9
Ethanol Approved Phase 4,Phase 1 64-17-5 702
10
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 184475-35-2 123631
11
Pemetrexed Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 150399-23-8, 137281-23-3 446556 60843
12
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
13
Nedaplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 95734-82-0
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
16
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
17
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
20
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
22
Acitretin Approved Phase 4,Phase 2 55079-83-9 6437841 5284513
23
Petrolatum Approved Phase 4 8009-03-8
24 Titanium dioxide Approved Phase 4 13463-67-7
25
Morphine Approved, Investigational Phase 4 57-27-2 5288826
26
Raltitrexed Approved, Investigational Phase 4,Phase 3 112887-68-0 104758
27
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
30
Mycophenolic acid Approved Phase 4 24280-93-1 446541
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 11103-57-4, 68-26-8 445354
34
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 114977-28-5 148124 9877265
35
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
36 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
45 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
46 interferons Phase 4,Phase 2,Phase 3,Phase 1
47 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2015)

id Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
3 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
4 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
5 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
6 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
7 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4 Nolbaxol;Taxotere;cisplatin
8 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
9 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
10 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
11 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
12 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
13 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
14 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
15 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
16 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
17 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
18 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
19 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Recruiting NCT02513342 Phase 4 Docetaxel;Cisplatin
20 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Recruiting NCT02495064 Phase 4 Mometasone Furoate Cream
21 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
22 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Recruiting NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
23 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
24 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Active, not recruiting NCT00684385 Phase 4 ZD1839
25 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
26 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
27 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
28 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Not yet recruiting NCT03196843 Phase 4 Raltitrexed
29 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4 Chemopreventive application (Acitretin)
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
31 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
32 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
33 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
34 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
35 Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
36 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
37 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
38 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
39 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
40 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
41 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
42 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
43 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
44 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
45 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
46 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
47 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
48 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
49 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
50 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod

Search NIH Clinical Center for Squamous Cell Carcinoma

Cochrane evidence based reviews: neoplasms, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

id Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 29
2 Squamous Cell Carcinoma of the Skin 29

Anatomical Context for Squamous Cell Carcinoma

MalaCards organs/tissues related to Squamous Cell Carcinoma:

39
Lung, Skin, Lymph Node, Tongue, Cervix, Endothelial, T Cells

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 11838)
id Title Authors Year
1
Vitamin D Signaling Pathways Confer the Susceptibility of Esophageal Squamous Cell Carcinoma in a Northern Chinese Population. ( 28362172 )
2017
2
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. ( 28950289 )
2017
3
Gemcitabine-based chemotherapy in colon squamous cell carcinoma: A case report and literature review. ( 28413669 )
2017
4
RICTOR expression in esophageal squamous cell carcinoma and its clinical significance. ( 28132115 )
2017
5
Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. ( 28411370 )
2017
6
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )
2017
7
Salivary MMP-1, MMP-2, MMP-3 and MMP-13 Levels in Patients with Oral Lichen Planus and Squamous Cell Carcinoma ( 28749626 )
2017
8
Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. ( 28672959 )
2017
9
DNA Methylation Status of PAX1 and ZNF582 in Esophageal Squamous Cell Carcinoma. ( 28241446 )
2017
10
Overexpressed PTOV1 associates with tumorigenesis and progression of esophageal squamous cell carcinoma. ( 28651486 )
2017
11
DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients. ( 27825810 )
2017
12
[Overexpression of OLC1 in Lung Squamous Cell Carcinoma Tissues is Associated with Poor Prognosis of Patients]. ( 28532543 )
2017
13
Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miRa89375. ( 27878285 )
2017
14
Association of Casp3 microRNA Target Site (1049216) SNP With the Risk and Progress of Cervical Squamous Cell Carcinoma. ( 28114230 )
2017
15
Basaloid Squamous Cell Carcinoma of the Head and Neck: Subclassification into Basal, Ductal, and Mixed Subtypes Based on Comparison of Clinico-pathologic Features and Expression of p53, Cyclin D1, Epidermal Growth Factor Receptor, p16, and Human Papillomavirus. ( 28593937 )
2017
16
Integrative genomic analysis identifies ancestry-related expression quantitative trait loci on DNA polymerase I^ and supports the association of genetic ancestry with survival disparities in head and neck squamous cell carcinoma. ( 27906459 )
2017
17
Endosonography and Confocal Endomicroscopy of Primary Keratinizing Squamous Cell Carcinoma of the Pancreas. ( 28184374 )
2017
18
Upregulated Expression of Transient Receptor Potential Cation Channel Subfamily V Receptors in Mucosae of Patients with Oral Squamous Cell Carcinoma and Patients with a History of Alcohol Consumption or Smoking. ( 28081185 )
2017
19
Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )
2017
20
Cancer stem cell markers in patterning differentiation and in prognosis of oral squamous cell carcinoma. ( 28631562 )
2017
21
Incidence trends and survival of skin melanoma and squamous cell carcinoma in Cluj County, Romania. ( 28914690 )
2017
22
Oligometastatic Stomach Carcinoma From Lung Squamous Cell Carcinoma Detected by 18F-FDG PET/CT. ( 28719444 )
2017
23
Downregulation of ST6GALNAC1 is associated with esophageal squamous cell carcinoma development. ( 28035351 )
2017
24
Sex-Determining Region Y-box 2 Promotes Growth of Lung Squamous Cell Carcinoma and Directly Targets Cyclin D1. ( 28151013 )
2017
25
Loss of PTEN Expression Is Associated With High MicroRNA 24 Level and Poor Prognosis in Patients With Tongue Squamous Cell Carcinoma. ( 28413152 )
2017
26
Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma. ( 28314263 )
2017
27
Correlation Between Squamous Cell Carcinoma Antigen Level and the Clinicopathological Features of Early-Stage Cervical Squamous Cell Carcinoma and the Predictive Value of Squamous Cell Carcinoma Antigen Combined With Computed Tomography Scan for Lymph Node Metastasis. ( 28914639 )
2017
28
The expression and significance of the HOXA7 gene in oral squamous cell carcinoma. ( 28529281 )
2017
29
Superior orbitectomy and chemotherapy in a dog with frontal sinus squamous cell carcinoma: a case report and review of the literature. ( 28396780 )
2017
30
Risks of different skin tumor combinations after a first melanoma, squamous cell carcinoma and basal cell carcinoma in Dutch population based cohorts: 1989 - 2009. ( 28898461 )
2017
31
Outcomes of sinonasal squamous cell carcinoma with and without association of inverted papilloma: A multi-institutional analysis. ( 28859706 )
2017
32
PTEN allelic loss is an important mechanism in the late stage of development of oral leukoplakia into oral squamous cell carcinoma. ( 28858374 )
2017
33
The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. ( 28724602 )
2017
34
Cryptotanshinone sensitizes antitumor effect of paclitaxel on tongue squamous cell carcinoma growth by inhibiting the JAK/STAT3 signaling pathway. ( 28946186 )
2017
35
Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )
2017
36
XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. ( 26918827 )
2017
37
Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth. ( 28794006 )
2017
38
Human Papillomavirus Investigation in Head and Neck Squamous Cell Carcinoma: Initial Report from the Low Risk HPV Types Associations ( 28952562 )
2017
39
Stathmin1 overexpression in hypopharyngeal squamous cell carcinoma: A new promoter in FaDu cell proliferation and migration. ( 27878293 )
2017
40
CCAR2 Is Required for Proliferation and Tumor Maintenance in Human Squamous Cell Carcinoma. ( 27725203 )
2017
41
Oral leukoplakia and oral cavity squamous cell carcinoma. ( 28916027 )
2017
42
A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma. ( 28835135 )
2017
43
Serum metabolomics in oral leukoplakia and oral squamous cell carcinoma. ( 28862226 )
2017
44
Development and Validation of the Basal and Squamous Cell Carcinoma Quality of Life Questionnaire. ( 28952653 )
2017
45
miR-202 Promotes Cell Apoptosis in Esophageal Squamous Cell Carcinoma by Targeting HSF2. ( 28277193 )
2017
46
Penile amebiasis mimicking penile squamous cell carcinoma. ( 28083900 )
2017
47
A comprehensive analysis of candidate gene signatures in oral squamous cell carcinoma. ( 28043142 )
2017
48
ZEB1 induced miR-99b/let-7e/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. ( 28408353 )
2017
49
Evaluation of vaginal fluid squamous cell carcinoma antigen test in diagnosis of premature rupture of membranes. ( 27095020 )
2017
50
Papillary squamous cell carcinoma of the palatine tonsil: a rare cancer of the head and neck. ( 28530265 )
2017

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6 (show all 23)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
4 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
5 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
7 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
8 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
9 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
10 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
11 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
12 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
13 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
14 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
15 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
16 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
17 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
18 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
19 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
20 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
21 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
22 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
23 DDR2 NM_001014796.2(DDR2): c.2304T> A (p.Ser768Arg) single nucleotide variant Pathogenic rs267598140 GRCh37 Chromosome 1, 162748390: 162748390

Cosmic variations for Squamous Cell Carcinoma:

9 (show top 50) (show all 639)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10726 TP53 skin,face,carcinoma,squamous cell carcinoma c.856G>A p.E286K 26
2 COSM10656 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 26
3 COSM43665 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 26
4 COSM10988 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 26
5 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 26
6 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 26
7 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 26
8 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 26
9 COSM17489 PTCH1 skin,face,carcinoma,squamous cell carcinoma c.3724G>A p.E1242K 26
10 COSM585 NRAS skin,face,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 26
11 COSM574 NRAS skin,face,carcinoma,squamous cell carcinoma c.38G>T p.G13V 26
12 COSM564 NRAS skin,face,carcinoma,squamous cell carcinoma c.35G>A p.G12D 26
13 COSM520 KRAS skin,face,carcinoma,squamous cell carcinoma c.35G>T p.G12V 26
14 COSM496 HRAS skin,arm,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 26
15 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 25
16 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 25
17 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 25
18 COSM573 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.38G>A p.G13D 25
19 COSM554 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.183A>C p.Q61H 25
20 COSM499 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 25
21 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 22
22 COSM10645 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.527G>T p.C176F 22
23 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 22
24 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 22
25 COSM45615 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.776A>G p.D259G 22
26 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 22
27 COSM11133 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>C p.C242S 22
28 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 22
29 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 22
30 COSM45248 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.805A>T p.S269C 22
31 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 22
32 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 22
33 COSM44633 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.583A>T p.I195F 22
34 COSM45135 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673-1G>T p.? 22
35 COSM11677 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.925C>T p.P309S 22
36 COSM11166 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 22
37 COSM10859 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>T p.V272L 22
38 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 22
39 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 22
40 COSM44821 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.412G>A p.A138T 22
41 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 22
42 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 22
43 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 22
44 COSM45636 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.934A>T p.T312S 22
45 COSM11066 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.578A>T p.H193L 22
46 COSM43564 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.708C>A p.Y236* 22
47 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 22
48 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 22
49 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 22
50 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 22

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number IGSF4 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain LOC440123 Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain DKFZP434F0318 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain LOC399986 Squamous cell cancer
18 66579 12 3100000 5300000 Gain LOC441627 Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1DN11-6 Squamous cell cancer
25 95699 15 79500000 83000000 Loss LOC159170 Squamous cell cancer
26 95701 15 79500000 83000000 Loss LOC161527 Squamous cell cancer
27 95703 15 79500000 83000000 Loss LOC388152 Squamous cell cancer
28 95705 15 79500000 83000000 Loss LOC388160 Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss LOC440301 Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain C19orf19 Squamous cell cancer
39 124168 19 1 6900000 Gain C19orf20 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain SCHC2 Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain EVI1 Squamous cell cancer
50 171549 3 169200000 172500000 Gain LOC389174 Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search GEO for disease gene expression data for Squamous Cell Carcinoma.

Pathways for Squamous Cell Carcinoma

Pathways related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
2
Show member pathways
13.77 CCND1 CDKN2A DDR2 EGFR ERBB2 HRAS
3
Show member pathways
12.94 CCND1 EGFR ERBB2 HRAS PTEN PTGS2
4
Show member pathways
12.82 ERBB2 HRAS PTEN PTGS2 TP53
5
Show member pathways
12.75 EGFR ERBB2 HRAS PTEN TP53
6 12.72 CCND1 EGFR HRAS PTEN PTGS2 RB1
7
Show member pathways
12.55 EGFR ERBB2 HRAS PTEN TP53
8 12.55 CCND1 CDKN2A GSTP1 RB1 TP53 TP63
9
Show member pathways
12.53 EGFR ERBB2 HRAS TP53
10
Show member pathways
12.51 CCND1 CDKN2A EGFR ERBB2 GSTP1 HRAS
11
Show member pathways
12.5 EGFR ERBB2 HRAS TGFBR2 TP53
12 12.47 CCND1 CDKN2A HRAS RB1 TGFBR2 TP53
13
Show member pathways
12.43 CCND1 CDKN2A PTEN RB1 TP53
14
Show member pathways
12.41 CCND1 HRAS PTEN TP53
15 12.38 CCND1 CDKN2A RB1 TP53
16
Show member pathways
12.37 CCND1 CDKN2A RB1 TP53
17
Show member pathways
12.37 CCND1